Urothelial Cancer

Publication Date: May 24, 2021
Last Updated: March 14, 2022

Diagnostic tests and biomarkers for urothelial cancer immunotherapy

  • Currently, the evidence does not support routine use of biomarkers to guide BCG therapy in NMIBC. Cystoscopy (with biopsy/transurethral resection (TUR) of bladder tumor as needed), urine cytology, and periodic upper tract imaging should be used to detect recurrence.

Non-muscle-invasive bladder cancer

  • BCG is recommended for all eligible patients with high-risk NMIBC (including cases with CIS or papillary tumors).
(Level 1)



Urothelial Cancer

Authoring Organization